MedicaidPrior AuthLow impact
Jevtana® (cabazitaxel)
Humana·OH · Oncology·Medicaid
Effective date
Sep 1, 2025
We identified it
Jun 24, 2026
Summary
Humana Ohio Medicaid has established a new prior authorization policy for Jevtana (cabazitaxel) chemotherapy for hormone-refractory metastatic prostate cancer, effective September 1, 2025. The policy requires prior approval based on specific clinical criteria including previous docetaxel treatment and concurrent corticosteroid use.
Action Required
By September 1, 2025: Billing team and oncology providers must obtain prior authorization before prescribing or billing for Jevtana (cabazitaxel) for Ohio Medicaid members. Update EMR to include reminder for three required criteria: hormone-refractory metastatic prostate cancer diagnosis, previous docetaxel treatment, and concurrent corticosteroid use. Verify patient does not have neutrophils ≤1,500/mm3, severe hepatic impairment, or concurrent use of abiraterone or enzalutamide. Claims without prior authorization will be denied.